AZD4076

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Non-alcoholic Steatohepatitis (NASH)T2DM With NAFLD

Phase 1

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

CompletedNCT02612662

AstraZenecaNon-alcoholic Steatohepatitis (NASH)

Start: 2015-11-24End: 2025-10-27Updated: 2025-11-19

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

CompletedNCT02826525

AstraZenecaT2DM With NAFLD

Start: 2016-07-18End: 2019-10-11Updated: 2021-04-01